Lyra Therapeutics, Inc.

OTCPK:LYRA Stock Report

Market Cap: US$1.3m

Lyra Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lyra Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Jun 16

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Summary Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, strong supporting data, and a good explanation for the ENLIGHTEN-1 failure, I believe the market is underestimating the potential for NDA submission without the need of another phase 3. Assuming positive FDA feedback, I expect considerable upside, allowing LYRA to raise much needed cash from a strong position. However, the FDA asking for another phase 3 trial would delay commercialization by several years. Without a partnership or other transaction, this would mean considerable dilution. Read the full article on Seeking Alpha
Analysis Article • Jan 25

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Sep 10

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 05

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics (NASDAQ:LYRA) has appointed Dr. Richard Nieman as Chief Medical Officer, effective July 11, 2022.  The industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the company's late-stage product candidates advance in the clinic. Dr. Nieman assumes the role of Chief Medical Officer, previously held by Dr. Robert Kern, who will continue to work closely with the company in the role of Chief Clinical Advisor. The firm has approved the issuance of an equity-based award pursuant to its 2022 Inducement Award Plan to Dr. Nieman upon the commencement of his employment.  The inducement grant consists of a non-qualified stock option to purchase an aggregate of 230,000 shares of the company's common stock.
Seeking Alpha • May 18

Lyra Therapeutics: Progress In The Clinic

Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile. The company is well funded. In this risk-off environment, there may be an even better entry point for investors.
Seeking Alpha • Apr 21

A First Look At Lyra Therapeutics

Today, we put Lyra Therapeutics in the spotlight for the first time. This small biopharma concern has disappointed investors since coming public in mid-2020. The drop in the shares has triggered some huge insider buying by insiders and beneficial owners of the stock via a capital raise in April. Time to buy this equity? A full investment analysis follows in the paragraphs below.
Analysis Article • Mar 30

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 14

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lyra Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:LYRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20250-29-29-29N/A
9/30/20251-33-34-34N/A
6/30/20251-39-43-43N/A
3/31/20251-80-57-56N/A
12/31/20242-93-72-70N/A
9/30/20241-98-81-78N/A
6/30/20242-101-79-76N/A
3/31/20242-69-73-70N/A
12/31/20232-63-64-63N/A
9/30/20231-62-57-56N/A
6/30/20231-61-53-53N/A
3/31/20231-60-47-47N/A
12/31/20221-55-44-43N/A
9/30/20222-55-44-43N/A
6/30/20221-51-44-42N/A
3/31/20221-48-32-30N/A
12/31/20210-44-29-26N/A
9/30/20210-37-24-20N/A
6/30/2021N/A-32-17-14N/A
3/31/2021N/A-26-28-25N/A
12/31/2020N/A-22-23-21N/A
9/30/2020N/A-20-20-19N/A
6/30/2020N/A-18-19-19N/A
3/31/2020N/A-17-15-15N/A
12/31/2019N/A-17-14-14N/A
12/31/20181-6N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LYRA's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if LYRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if LYRA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LYRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if LYRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LYRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:34
End of Day Share Price 2026/07/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lyra Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Matthew CaufieldH.C. Wainwright & Co.
Christopher HowertonJefferies LLC